201 related articles for article (PubMed ID: 34251810)
1. Delineating the Ligand-Receptor Interactions That Lead to Biased Signaling at the μ-Opioid Receptor.
Kelly B; Hollingsworth SA; Blakemore DC; Owen RM; Storer RI; Swain NA; Aydin D; Torella R; Warmus JS; Dror RO
J Chem Inf Model; 2021 Jul; 61(7):3696-3707. PubMed ID: 34251810
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
Mafi A; Kim SK; Goddard WA
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Evolution of G Protein-Biased μ-Opioid Receptor Agonists.
Wang H; Hetzer F; Huang W; Qu Q; Meyerowitz J; Kaindl J; Hübner H; Skiniotis G; Kobilka BK; Gmeiner P
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202200269. PubMed ID: 35385593
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition of morphine and fentanyl by the human μ-opioid receptor.
Zhuang Y; Wang Y; He B; He X; Zhou XE; Guo S; Rao Q; Yang J; Liu J; Zhou Q; Wang X; Liu M; Liu W; Jiang X; Yang D; Jiang H; Shen J; Melcher K; Chen H; Jiang Y; Cheng X; Wang MW; Xie X; Xu HE
Cell; 2022 Nov; 185(23):4361-4375.e19. PubMed ID: 36368306
[TBL] [Abstract][Full Text] [Related]
5. Molecular insights into the biased signaling mechanism of the μ-opioid receptor.
Cong X; Maurel D; Déméné H; Vasiliauskaité-Brooks I; Hagelberger J; Peysson F; Saint-Paul J; Golebiowski J; Granier S; Sounier R
Mol Cell; 2021 Oct; 81(20):4165-4175.e6. PubMed ID: 34433090
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of Novel Biased μ-Opioid-Receptor (μOR) Agonists.
Ma M; Sun J; Li M; Yu Z; Cheng J; Zhong B; Shi W
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641969
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of salsolinol, a full G
Berríos-Cárcamo P; Rivera-Meza M; Herrera-Marschitz M; Zapata-Torres G
Chem Biol Drug Des; 2019 Aug; 94(2):1467-1477. PubMed ID: 30920734
[TBL] [Abstract][Full Text] [Related]
8. Probing Allosteric Regulation Mechanism of W7.35 on Agonist-Induced Activity for μOR by Mutation Simulation.
Zhang F; Chen X; Chen J; Xu Y; Li S; Guo Y; Pu X
J Chem Inf Model; 2022 Nov; 62(21):5120-5135. PubMed ID: 34779608
[TBL] [Abstract][Full Text] [Related]
9. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
French AR; van Rijn RM
Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
[TBL] [Abstract][Full Text] [Related]
10. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.
Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX
Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Structural Explorations of G-Protein Biased μ-Opioid Receptor Agonists.
Li X; Guo Y; Li J; Yu Z; Cheng J; Ren F; Jia H; Zhang Y; Cui S; Zhang T; Shi W
ChemMedChem; 2022 Dec; 17(24):e202200416. PubMed ID: 36210341
[TBL] [Abstract][Full Text] [Related]
12. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists.
Stahl EL; Schmid CL; Acevedo-Canabal A; Read C; Grim TW; Kennedy NM; Bannister TD; Bohn LM
Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819362
[TBL] [Abstract][Full Text] [Related]
13. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.
Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
Acta Pharmacol Sin; 2018 Jan; 39(1):154-164. PubMed ID: 29188799
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Conformational Equilibrium That Determines the Efficacy and Functional Selectivity of the μ-Opioid Receptor.
Okude J; Ueda T; Kofuku Y; Sato M; Nobuyama N; Kondo K; Shiraishi Y; Mizumura T; Onishi K; Natsume M; Maeda M; Tsujishita H; Kuranaga T; Inoue M; Shimada I
Angew Chem Int Ed Engl; 2015 Dec; 54(52):15771-6. PubMed ID: 26568421
[TBL] [Abstract][Full Text] [Related]
15. An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.
Groer CE; Tidgewell K; Moyer RA; Harding WW; Rothman RB; Prisinzano TE; Bohn LM
Mol Pharmacol; 2007 Feb; 71(2):549-57. PubMed ID: 17090705
[TBL] [Abstract][Full Text] [Related]
16. Insights into distinct signaling profiles of the µOR activated by diverse agonists.
Qu Q; Huang W; Aydin D; Paggi JM; Seven AB; Wang H; Chakraborty S; Che T; DiBerto JF; Robertson MJ; Inoue A; Suomivuori CM; Roth BL; Majumdar S; Dror RO; Kobilka BK; Skiniotis G
Nat Chem Biol; 2023 Apr; 19(4):423-430. PubMed ID: 36411392
[TBL] [Abstract][Full Text] [Related]
17. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
[TBL] [Abstract][Full Text] [Related]
18. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists.
Kelly E; Conibear A; Henderson G
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():491-515. PubMed ID: 36170657
[TBL] [Abstract][Full Text] [Related]
19. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias.
Pineyro G; Nagi K
Cell Signal; 2021 Apr; 80():109906. PubMed ID: 33383156
[TBL] [Abstract][Full Text] [Related]
20. Biased Opioid Ligands.
Faouzi A; Varga BR; Majumdar S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
